chlorpromazine + pentobarbital

**Chlorpromazine + pentobarbital** is a combination of two pharmaceutical drugs: **chlorpromazine**, a first-generation (typical) antipsychotic, and **pentobarbital**, a barbiturate sedative. **Chlorpromazine** acts primarily as an antagonist of dopamine D2 receptors in the central nervous system, reducing dopamine activity and thereby treating psychiatric disorders such as schizophrenia and bipolar disorder; it is also used for nausea, vomiting, preoperative sedation, hiccups, porphyria, and agitation[2][4][7][8][10]. **Pentobarbital** is a central nervous system depressant used for short-term treatment of insomnia, sedation, and seizure control; it acts mainly by potentiating GABA-A receptor activity and inhibiting excitatory neurotransmission at AMPA-type glutamate receptors[6]. The combination has been explored in scientific studies to investigate their joint effects on behavior, cerebral hemodynamics, and metabolism, especially in experimental or perioperative sedation settings[3][9]. No approved formulation or unique brand combines these drugs routinely, but they have been co-administered in research and clinical practice for their sedative additive effects.